Cargando…
Cisplatin plus vinorelbine as induction treatment in stage IIIA non-small cell lung cancer
Survival rates in patients with stage IIIA non-small cell lung cancer (NSCLC) remain low despite curative treatment. This is due to tumor recurrence at distant sites. The aim of neoadjuvant chemotherapy (NA-CT) is to eradicate occult micrometastatic disease and improve survival in patients that are...
Autores principales: | Palka, Magda, Sanchez, Antonio, Córdoba, Mar, Nuevo, Gema Díaz, De Ugarte, Andrés Varela, Cantos, Blanca, Méndez, Miriam, Calvo, Virginia, Maximiano, Constanza, Provencio, Mariano |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5403378/ https://www.ncbi.nlm.nih.gov/pubmed/28454304 http://dx.doi.org/10.3892/ol.2017.5620 |
Ejemplares similares
-
Successful Concurrent Chemoradiotherapy with Cisplatin plus Vinorelbine for Locally Advanced Thymic Carcinoma
por: Fukushima, Toshirou, et al.
Publicado: (2014) -
Oral fluorouracil vs vinorelbine plus cisplatin as adjuvant chemotherapy for stage II‐IIIA non‐small cell lung cancer: Propensity score‐matched and instrumental variable analyses
por: Urushiyama, Hirokazu, et al.
Publicado: (2018) -
Monitoring with circulating tumor cells in the perioperative setting of patients with surgically treated stages I–IIIA NSCLC
por: Garitaonaindia, Yago, et al.
Publicado: (2023) -
Efficacy and Safety of Vinorelbine Plus Cisplatin vs. Gemcitabine Plus Cisplatin for Treatment of Metastatic Triple-Negative Breast Cancer After Failure with Anthracyclines and Taxanes
por: Wang, Junbin, et al.
Publicado: (2017) -
Gefitinib Versus Vinorelbine Plus Cisplatin as Adjuvant Treatment for Stage II-IIIA (N1-N2) EGFR-Mutant NSCLC: Final Overall Survival Analysis of CTONG1104 Phase III Trial
por: Zhong, Wen-Zhao, et al.
Publicado: (2021)